Literature DB >> 18418038

Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects.

Jürgen Knobloch1, Ulrich Rüther.   

Abstract

Many hypotheses have been proposed to explain the molecular mechanism of thalidomide teratogenicity, in particular regarding to limb defects. Most experimental evidence in vivo has been provided for a model that suggests the generation of oxidative stress by thalidomide with subsequent downregulation of Wnt and Akt survival pathways. As a consequence apoptosis is induced during early embryonic limb development resulting in limb truncations. Here we summarize and discuss the relevant data supporting this hypothesis. We extend this model by presenting new data demonstrating an involvement of the transcription factors Tbx5 and Sall4 in thalidomide-induced molecular pathology. Finally, we discuss a possible participation of other stress-responsive and/or pro-apoptotic transcription factors in the mechanism of thalidomide teratogenicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18418038     DOI: 10.4161/cc.7.9.5793

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  33 in total

1.  Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.

Authors:  Chad C Bjorklund; Wencai Ma; Zhi-Qiang Wang; R Eric Davis; Deborah J Kuhn; Steven M Kornblau; Michael Wang; Jatin J Shah; Robert Z Orlowski
Journal:  J Biol Chem       Date:  2010-12-28       Impact factor: 5.157

2.  What is the functional role of the thalidomide binding protein cereblon?

Authors:  Xiu-Bao Chang; A Keith Stewart
Journal:  Int J Biochem Mol Biol       Date:  2011-09-10

Review 3.  Phocomelia: a worldwide descriptive epidemiologic study in a large series of cases from the International Clearinghouse for Birth Defects Surveillance and Research, and overview of the literature.

Authors:  Eva Bermejo-Sánchez; Lourdes Cuevas; Emmanuelle Amar; Sebastiano Bianca; Fabrizio Bianchi; Lorenzo D Botto; Mark A Canfield; Eduardo E Castilla; Maurizio Clementi; Guido Cocchi; Danielle Landau; Emanuele Leoncini; Zhu Li; R Brian Lowry; Pierpaolo Mastroiacovo; Osvaldo M Mutchinick; Anke Rissmann; Annukka Ritvanen; Gioacchino Scarano; Csaba Siffel; Elena Szabova; María-Luisa Martínez-Frías
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-10-14       Impact factor: 3.908

4.  Treatment of coronary artery disease via MIDCAB in a patient with severe thalidomide phocomelia.

Authors:  Maximilian Scherner; Maria Mihaijlova; Navid Madershahian; Thorsten Wahlers; Jens Wippermann
Journal:  Clin Res Cardiol       Date:  2013-08-06       Impact factor: 5.460

5.  Identification of the nuclear localization signal of SALL4B, a stem cell transcription factor.

Authors:  Meng Wu; Feikun Yang; Zhihua Ren; Yongping Jiang; Yupo Ma; Yan Chen; Wei Dai
Journal:  Cell Cycle       Date:  2014-03-10       Impact factor: 4.534

Review 6.  Epigenetics in comparative biology: why we should pay attention.

Authors:  Warren W Burggren; David Crews
Journal:  Integr Comp Biol       Date:  2014-04-09       Impact factor: 3.326

Review 7.  Teratogenic effects of thalidomide: molecular mechanisms.

Authors:  Takumi Ito; Hideki Ando; Hiroshi Handa
Journal:  Cell Mol Life Sci       Date:  2011-01-05       Impact factor: 9.261

8.  Thalidomide induces apoptosis in undifferentiated human induced pluripotent stem cells.

Authors:  Saoko Tachikawa; Toshinobu Nishimura; Hiromitsu Nakauchi; Kiyoshi Ohnuma
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-08-28       Impact factor: 2.416

9.  Development of the Proximal-Anterior Skeletal Elements in the Mouse Hindlimb Is Regulated by a Transcriptional and Signaling Network Controlled by Sall4.

Authors:  Katherine Q Chen; Naoyuki Tahara; Aaron Anderson; Hiroko Kawakami; Sho Kawakami; Ryuichi Nishinakamura; Pier Paolo Pandolfi; Yasuhiko Kawakami
Journal:  Genetics       Date:  2020-03-10       Impact factor: 4.562

Review 10.  Mechanism of action of lenalidomide in hematological malignancies.

Authors:  Venumadhav Kotla; Swati Goel; Sangeeta Nischal; Christoph Heuck; Kumar Vivek; Bhaskar Das; Amit Verma
Journal:  J Hematol Oncol       Date:  2009-08-12       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.